The Institute for Clinical and Economic Review’s (ICER) review process “relies on flawed assumptions,” and ultimately its process could “undermine research into rare diseases,” the author of a recent opinion piece published in the San Francisco Examiner writes.
The author, former Easterseals president and CEO Randall Rutta, takes aim at the quality-adjusted life year (QALY) ICER uses in its cost-effectiveness analysis.
“From the outset, this metric effectively discriminates against elderly and sick people, persons with chronic conditions, as well as people living with disabilities,” Rutta writes. “ICER’s position is that these individuals aren’t in perfect health to begin with. So, the group doesn’t count an additional 12 months of life expectancy as a full QALY.”
To read the full article, click here.